A recent analysis of a phase III study (BMS099; taxane/carboplatin with or without cetuximab; no radiotherapy) where tumour samples from 225 patients were examined, did not find significant associations between KRAS and EGFR and various outcome parameters [36]. The gene discussed is EGFR; the disease is neoplasm.